Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30833139.
- Also identified by DOI 10.1016/j.eururo.2019.02.027.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
It has been demonstrated that immune checkpoint blockade has efficacy similar to chemotherapy in the neoadjuvant setting. Biomarkers such as PD-L1 expression levels can be used to rationally design clinical trials aimed at personalizing systemic therapy for patients with muscle-invasive bladder cancer.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- Neoadjuvant Therapy
- Urinary Bladder Neoplasms